Geneesmiddelen

Blinatumomab ^IND

Cusatuzumab Enasidenib Gilteritinib Glasdegib Idasanutlin Imetelstat Iomab-B

Ivosidenib

Relapsed or refractory isocitrate dehydrogenase-1 (IDH-1) mutation-positive acute myeloid leukaemia Acute myeloid leukaemia (AML), isocitrate dehydrogenase-1 (IDH1) mutation - first-line combination therapy.

Luspatercept Sapacitabine Venetoclax ^IND

Brentuximab vedotin ^IND Lisocabtagene maraleucel Mogamulizumab Polatuzumab vedotin Rituximab ^IND Tafasitamab Tagraxofusp

Zanubrutinib

Mantelcel non-hodgkin lymfoom Waldenström's macroglobulinaemia (WM) Chronische Lymfatische Leukemie (CLL) Mantle-cell lymphoma

Atezolizumab

Tecentriq is als monotherapie geïndiceerd voor de behandeling van volwassen patiënten met lokaal gevorderd of gemetastaseerd urotheelcarcinoom (UC) na eerdere behandeling met platina-bevattende chemotherapie of voor wie cisplatine ongeschikt is. ^IND Extension of indication to include, in combination with platinum-based chemotherapy, first-line treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) for Tecentriq. ^IND Adjuvant treatment after surgical resection of high-risk muscle-invasive bladder cancer (MIBC). ^IND

Avelumab ^IND Durvalumab ^IND Enfortumab vedotin Oportuzumab monatox Pembrolizumab ^IND Tremelimumab

Asunercept Brain cancer vaccine ERC1671 Tasadenoturev Vocimagene amiretrorepvec

Abemaciclib ^IND Alpelisib

Atezolizumab

Neoadjuvant treatment for patients with early TNBC in combination with nab-paclitaxel. ^IND treatment of patients with previously untreated metastatic TNBC in combination with paclitaxel ^IND

Margetuximab Neratinib Paclitaxel

Pembrolizumab

Breast cancer, metastatic, triple negative, 1L. ^IND Triple Negative Breast Cancer - Neoadjuvant ^IND

Pertuzumab / trastuzumab ^IND Sacituzumab govitecan Talazoparib Trastuzumab deruxtecan Trastuzumab duocarmazine

Trastuzumab emtansine

Kadcyla, as a single agent, is indicated for the adjuvant treatment of adult patients with HER2-positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2-targeted therapy. ^IND Trastuzumab entansine in combination with pertuzumab following anthracyclines as adjuvant therapy in patients with operable HER2-positive primary breast cancer. ^IND

Tucatinib ^G Veliparib

Acalabrutinib

1L CLL in combinatie met obinutuzumab Behandeling van relapsed/refractory CLL (chronic lymphocytic leukemia).

Duvelisib Ibrutinib ^IND Moxetumomab pasudotox

Venetoclax

Venclyxto in combinatie met rituximab is geïndiceerd voor de behandeling van volwassen patiënten met chronische lymfatische leukemie (CLL) die ten minste één andere therapie hebben gehad. ^IND Venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL). ^IND

Eflornithine / sulindac Encorafenib ^IND

Afatinib ^IND Avelumab ^IND Brilacidin Durvalumab ^IND Leukocyte interleukin Pembrolizumab ^IND Tremelimumab

Carmustine ^G Fostamatinib Lusutrombopag pegfilgrastim

Axicabtagene ciloleucel ^IND Copanlisib

Ibrutinib

Follicular lymphoma (FL), relapsed / refractory. ^IND Marginal zone lymphoma (MZL), relapsed / refractory. ^IND

Lenalidomide ^IND Umbralisib

Avelumab ^IND Ipilimumab ^IND Pembrolizumab ^IND Tivozanib ^IND

Asciminib

Atezolizumab ^IND Pemigatinib

Atezolizumab

For the 1L treatment of patients with metastatic, squamous NSCLC in combination with chemotherapy ^IND Extension of indication to include the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumours express PD-L1. ^IND

Avelumab ^IND Brigatinib ^IND Canakinumab ^IND Dacomitinib

Durvalumab

Non-small cell lung cancer (NSCLC) stage IV, in combination with chemo, 1L. ^IND Extension of indication to include the use of IMFINZI in combination with etoposide and either carboplatin or cisplatin for the first-linetreatment of adults with extensive-stage small cell lung cancer (ES-SCLC). ^IND

Entrectinib Lorlatinib Lurbinectedin Nivolumab ^IND Osimertinib ^IND

Pembrolizumab

Extension of Indication to include 1st line treatment of locally advanced or metastatic non-small cell lung cancer tumours expressing PD-L1 with a ≥ 1% tumour proportion score (TPS). ^IND Pembrolizumab in Combination with Etoposide/Platinum (Cisplatin or Carboplatin) for the treatmen of extensive stage Small Cell Lung Cancer (SCLC) (1L) ^IND

Ramucirumab ^IND Selpercatinib

Tremelimumab

Non-small cell lung cancer (NSCLC) stage IV, in combination with durvalumab and chemo, 1L. Untreated extensive-stage small cell lung cancer (SCLC) in combination with durvalumab and chemotherapy.

Nivolumab ^IND

Belantamab mafodotin Carfilzomib ^IND

Daratumumab

Extension of indication to extend the existing therapeutic indication for daratumumab in combination with bortezomib, thalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant (ASCT). ^IND Extension of indication to extend the existing therapeutic indication for daratumumab in combination with lenalidomide and dexamethasone (Rd) for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT). ^IND Amyloidose eerstelijnsbehandeling in combinatie met bortezomib, cyclofosfamide en dexamethason ^IND In combinatie met pomalidomide en dexamethason voor patiënten met multipel myeloom die tenminste een eerdere lijn van behandeling hebben gehad. ^IND Subcutaneous formulation indicates for Relapsed or Refractory Multiple Myeloma ^IND

Ibrutinib ^IND Idecabtagene vicleucel

Isatuximab

Sarclisa is indicated, in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (MM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (PI) and have demonstrated disease progression on the last therapy. Combinatie van isatuximab met carfilzomib en dexamethason bij patiënten met gerecidiveerd en refractair multipel myeloom na 1 tot maximaal 3 eerdere behandellijnen. ^IND

Ixazomib

Newly diagnosed Multiple Myeloma (MM) ^IND Non-ASCT maintenance Multiple Myeloma (MM) ^IND

Lenalidomide ^IND Pomalidomide ^IND Selinexor

Fedratinib Ropeginterferon alfa-2b

L-lysine / L-arginine Selumetinib Surufatinib

Dostarlimab Entrectinib ^IND Erlotinib ^G Ivosidenib ^IND Larotrectinib Nivolumab ^IND

Pembrolizumab

1L Colorectaalcarcinoom, MSI-High ^IND Treatment of recurrent locally advanced or metastatic oesophageal cancer in adults whose tumours express PD L1 with a CPS ≥ 10 and who have received prior systemic therapy. ^IND

Pexidartinib Sodium thiosulfate

Atezolizumab ^IND Niraparib ^IND

Olaparib

Maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. ^IND Extension of indication to include the use of Lynparza tablets in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy with bevacizumab. ^IND

Veliparib

Eryaspase (Asparaginase) Olaparib ^IND

177Lu-PSMA617

Abiraterone

Geïndiceerd met prednison of prednisolon voor: - de behandeling van nieuw gediagnosticeerde hoog-risico gemetastaseerde hormoongevoelige prostaatkanker (mHSPC) bij volwassen mannen, in combinatie met androgeendeprivatietherapie (ADT); - de behandeling van gemetastaseerde castratieresistente prostaatkanker (mCRPC) bij volwassen mannen die asymptomatisch of licht symptomatisch zijn na falen van androgeendeprivatietherapie en voor wie behandeling met chemotherapie nog niet klinisch geïndiceerd is ; - de behandeling van mCRPC bij volwassen mannen bij wie de ziekte progressief was tijdens of na een chemotherapieschema op basis van docetaxel. ^G Geïndiceerd met prednison of prednisolon voor: - de behandeling van nieuw gediagnosticeerde hoog-risico gemetastaseerde hormoongevoelige prostaatkanker (mHSPC) bij volwassen mannen, in combinatie met androgeendeprivatietherapie (ADT); - de behandeling van gemetastaseerde castratieresistente prostaatkanker (mCRPC) bij volwassen mannen die asymptomatisch of licht symptomatisch zijn na falen van androgeendeprivatietherapie en voorwie behandeling met chemotherapie nog niet klinisch geïndiceerd is ; - de behandeling van mCRPC bij volwassen mannenbij wie de ziekte progressief was tijdens of na een chemotherapieschema op basis van docetaxel. ^BS

Abiraterone / apalutamide Apalutamide ^IND Cabazitaxel ^G Darolutamide DCVAC Enzalutamide ^IND Niraparib ^IND Olaparib ^IND Relugolix

Atezolizumab

mM 1L BRAF wild type in combinatie met cobimetinib ^IND mM 1L BRAF+ in combinatie met cobimetinib en vemurafenib. ^IND

Cemiplimab

Monotherapy treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation. Libtayo wordt onderzocht in patiënten met gevorderd basaalcelcarcinoom van de huid (cBCC) die progressie vertonen onder behandeling met hedgehog inhibitor therapie of intolerant waren voor eerdere behandeling met hedgehog inhibitor therapie. ^IND

Dabrafenib / Trametinib ^IND Lifileucel Seviprotimut-L Spartalizumab Tavokinogene telseplasmid

Axicabtagene ciloleucel

Yescarta is geïndiceerd voor de behandeling van volwassen patiënten met recidiverend of refractair diffuus grootcellig B-cellymfoom (DLBCL) en primair mediastinaal grootcellig B-cellymfoom (PMBCL), na twee of meer lijnen systemische therapie. Recidiverend of refractair na 1 of meer lijnen van therapie DLBCL.

BL-8040 Ibrutinib ^IND Inolimomab Itacitinib KTE-X19 LCAR-B38M CAR-T cell therapy Narsoplimab Remestemcel-L Rimiducid Rivogenlecleucel Ruxolitinib ^IND Tabelecleucel Tisagenlecleucel-T Treosulfan

Avapritinib Masitinib Ripretinib Rivoceranib

Selpercatinib

Informatie over geneesmiddelen die in de nabije toekomst op de markt verwacht worden.

Oncology and Hematology

ALL

Dasatinib

AML / MDS

Arseentrioxide

Azacitidine

Ivosidenib

Aggressive non-Hodgkin's lymphoma

Zanubrutinib

Bladder cancer

Atezolizumab

Brain cancer

Breast cancer

Atezolizumab

Pembrolizumab

Trastuzumab emtansine

CLL

Acalabrutinib

Venetoclax

Colon cancer

Head and neck cancer

Hematology other

Indolent non-Hodgkin's lymphoma

Ibrutinib

Kidney cancer

Leukemia

Liver cancer

Lung cancer

Atezolizumab

Durvalumab

Pembrolizumab

Tremelimumab

Mesothelioma

Multiple Myeloma

Daratumumab

Isatuximab

Ixazomib

Myeloproliferative disorders

Neuroendocrine cancer

Other oncology

Pembrolizumab

Ovarian cancer

Olaparib

Pancreatic cancer

Prostate cancer

Abiraterone

Skin cancer

Atezolizumab

Cemiplimab

Stem cell transplants

Axicabtagene ciloleucel

Stomach cancer

Thyroid cancer

Service

About this site